Cargando…
Immune Checkpoint Inhibitors in Special Populations
Cancer is the second leading cause of death in the worldwide. With the growing burden of cancer, the studies on early diagnosis, treatment and prevention of cancer are rapidly increasing. Recently, many new therapeutic strategies have been discovered, among which immunotherapy has dramatically chang...
Autores principales: | Shan, Qianyun, Lu, Hongyang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371726/ https://www.ncbi.nlm.nih.gov/pubmed/34384286 http://dx.doi.org/10.1177/15330338211036526 |
Ejemplares similares
-
Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach?
por: Bronte, Giuseppe, et al.
Publicado: (2023) -
Treatment of Cutaneous Squamous Cell Carcinoma with Immune Checkpoint Inhibitors in Special Populations
por: Bossi, Paolo, et al.
Publicado: (2021) -
Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populations
por: Wang, Jun, et al.
Publicado: (2023) -
Future of immune checkpoint inhibitors: focus on tumor immune microenvironment
por: Jia, Yunlong, et al.
Publicado: (2020) -
Cardiotoxicity of immune checkpoint inhibitors
por: Varricchi, Gilda, et al.
Publicado: (2017)